Business Wire

Unifrax Announces SiFAB™ Manufacturing Line

15.6.2021 14:00:00 EEST | Business Wire | Press release

Share

Unifrax, a Buffalo, New York headquartered global manufacturer of high-performance specialty materials, announced plans today to build its first large-scale SiFAB (silicon fiber anode material) manufacturing line at its north central Indiana facility that could add up to 74 new jobs by the end of 2023.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210615005391/en/

SiFAB is a proprietary silicon anode battery technology which enables significantly greater energy density in lithium-ion battery systems than prevailing technologies. SiFAB is currently in advanced testing and has shown promising performance in multiple battery systems. The anode technology has successfully been tested with incremental Si loadings of greater than 40%. Along with greater energy density, SiFAB is expected to provide faster charges and longer battery life for applications including electric vehicles, portable electronics, power tools, energy grid storage and aerospace.

Unifrax is uniquely positioned to meet customer demand and develop SiFAB at scale, due to its existing manufacturing plant and infrastructure in New Carlisle. The Indiana plant will be the first to begin building SiFAB long-term manufacturing capacity. The new line is slated to create up to 20 new jobs by the end 2022, with additional growth anticipated by the end of 2023. Unifrax will have more information on open positions later this year on its website.

“SiFAB is the latest development using fiber-based technology to create step change value for customers. This transformational material represents another addition to our robust electric vehicle and battery solutions portfolio,” said John Dandolph, president and CEO, Unifrax. “Unifrax is a large, global manufacturing company introducing game changing advanced silicon anode materials that can be used in existing manufacturing processes. Our track record and proven ability to develop new and unique technologies will help transform the battery industry with SiFAB. The ability to leverage our existing facility and add new infrastructure to support SiFAB manufacturing in New Carlisle will significantly accelerate the timeline for supplying this critical material to our partners. We are appreciative of the ongoing partnership between the state of Indiana and St. Joseph County as we leverage the footprint of our existing facility to bring new jobs and opportunities to the region.”

“We designed SiFAB from its inception to be manufactured at large scale so that we could supply all market segments (EV’s, consumer electronics, power tools, and renewable storage), utilize our existing global manufacturing footprint, and deliver a product that has a high degree of quality and consistency,” said Chad Cannan, senior vice president of research and development, Unifrax.

The Indiana Economic Development Corporation offered Unifrax up to $1.1 million in conditional tax credits based on the company’s job creation plans. These tax credits are performance-based, meaning the company is eligible to claim incentives once Hoosiers are hired. St. Joseph County has also confirmed $775K in county tax incentives.

“Indiana is a leader in manufacturing, with the highest concentration of manufacturing jobs in the nation supported by 9,000 facilities across the state," said Jim Staton, interim secretary of commerce for the state of Indiana. “As new trends and technologies change the state of today’s manufacturing industry, Indiana is focused on partnering with forward-thinking companies like Unifrax to propel long-term growth in manufacturing and create quality career opportunities for Hoosiers.”

St. Joseph County Commissioner Andrew Kostielney also added, "The recent announcement by Unifrax is exciting news, not just for St. Joseph County, but for the entire region. Unifrax has long been an important manufacturing leader in the area, and this expansion indicates their commitment to our county for decades to come. Their new SiFAB line will not just create new jobs, it will also showcase the importance of green, sustainable technology."

After more than 75 years of experience in fiber-based technology and manufacturing, Unifrax is taking its first step into developing silicon fiber for the lithium-ion battery manufacturing market. With a decades-long track record of developing and supplying engineered inorganic materials at a large scale to advanced industries worldwide including electric vehicles, aerospace and chemical processing, Unifrax recently debuted two new fiber-based catalysis offerings for the automotive and industrial markets – Eco-lytic™ and FlexCat™.

To learn more about SiFAB, and to request a sample, Unifrax launched a new website introducing SiFAB with technical, manufacturing and application specific information. The new website can be found at sifab.com.

About Unifrax

Unifrax develops and manufactures high performance specialty materials used in advanced applications including high-temperature industrial insulation, electric vehicles, energy storage, filtration, and fire protection, among many others. Unifrax products are designed with the ultimate goal of saving energy, reducing pollution, and improving safety for people, buildings and equipment by delivering on our commitment to our customers of greener, cleaner, safer solutions for their application challenges. Unifrax has 37 manufacturing facilities operating in 12 countries and employs 2,700+ employees globally. More information is available at www.unifrax.com. For updates, follow us on Twitter, LinkedIn, and Facebook.

About Clearlake

Clearlake Capital Group, L.P. is a leading investment firm founded in 2006 operating integrated businesses across private equity, credit and other related strategies. With a sector-focused approach, the firm seeks to partner with experienced management teams by providing patient, long-term capital to dynamic businesses that can benefit from Clearlake’s operational improvement approach, O.P.S. ® The firm’s core target sectors are industrials, technology and consumer. Clearlake currently has approximately $39 billion of assets under management, and its senior investment principals have led or co-led over 300 investments. The firm has offices in Santa Monica and Dallas. More information is available at www.clearlake.com and on Twitter @ClearlakeCap.

About IEDC

The Indiana Economic Development Corporation (IEDC) leads the state of Indiana’s economic development efforts, helping businesses launch, grow and locate in the state. Governed by a 15-member board chaired by Governor Eric J. Holcomb, the IEDC manages many initiatives, including performance-based tax credits, workforce training grants, innovation and entrepreneurship resources, public infrastructure assistance, and talent attraction and retention efforts. For more information about the IEDC, visit www.iedc.in.gov.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Deborah L. Myers (Unifrax) – dmyers@unifrax.com or 716.812.4802
Jennifer Hurson (Clearlake Capital) – jhurson@lambert.com or 845.507.0571
Erin Sweitzer (IEDC) – 317.296.2556 or esweitzer@iedc.in.gov

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 15:32:00 EEST | Press release

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company's plans to advance the program globally. The FDA granted RPD Designation based on its determination that A-T is a serious and life-threatening disease that primarily affects individ

Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 15:00:00 EEST | Press release

Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT), sensor, and asset data. It helps organizations track and visualize public events, supply chains, and infrastructure to identify and respond to potential threats. ArcGIS Velocity for ArcGIS Enterprise expands cloud-native support to enterprise customers across industries in government and business that rely on firewall protection and internal security compliance. ArcGIS Velocity connects to more than 20 ready-to-use feeds for real-time data providers, including Dataminr, Samsara, Fli

HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 15:00:00 EEST | Press release

HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev

SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 15:00:00 EEST | Press release

Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, umbilical, manifolds, multiphase flowmeters and control systems, along with installation, commissionin

Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 13:00:00 EEST | Press release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of approximately $85 million in upfront gross proceeds, before the deduction of private placement expenses, and up to an additional $255 million upon the full exercise of purchase warrants. The financing was led by Commodore Capital, with participation from RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals. The net proceeds of this financing are expected to support Agenus’ strategic prioritization of botensilimab and balstilimab (BOT+BAL) for the neoadjuvant treatment of microsatellite-stable (MSS) colon cancer, including advancement of ROBBIN1, the Company’s planned registrational Phase 3 neoadjuvant trial in microsatellite-stable (MSS) colon cancer. High-risk Stage II and Stage III MSS colon cancer affect an estimated 38,000 patients annually in the US and more than 200,000 patients worldwide,2 representing a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye